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Abstract
Background: Heart failure (HF) patients can benefit from a proper RS. We had observed
that they show an increase in the number of arrhythmias during the first year of pharmacologi-
cal treatment.
Methods: We carried out a prospective observational study in which patients in an HF Clinic
were included when they had follow-up Holter monitoring. Patients also had a baseline myo-
cardial perfusion scan (Tc99 sestaMIBI/dypiridamole) and a control scan.
Results: We included 90 patients with follow-up Holter and 35 with scintigraphy, for analy-
sis. Fifty-six (62.2%) were men and the average age was 60.8 ± 14.6 years. Follow-up periods
were divided by six-month intervals up to 18 months or more, an increase in premature
ventricular contractions (PVCs) occurred in the six-month to one-year period (1915.4 ±
± 4686.9 vs. 2959 ± 6248.1, p = 0.09). In the one-year to 18-month control, PVCs went from
781.6 ± 1082.4 to 146.9 ± 184.1, p = 0.05. The increase in PVCs correlated with a reduction
in scintigraphy-detected ischemic territories, 5.64 ± 5.9 vs. 3.18 ± 3 (p = 0.1) and a gain in
those showing a reverse redistribution pattern (0.18 ± 0.6 vs. 2.09 ± 4.01, p = 0.1). Necrotic
territories and time domain heart rate variability did not show significant changes.
Conclusions: PVCs increase during the first year of HF treatment, and then they tend to
diminish and stabilize. These changes seem to correlate with changes in the perfusion state of
the patient. While ischemic territories decrease, reverse redistribution increases, showing that
endothelial dysfunction could have a relevant role in arrhythmia generation, possibly because
of membrane instability of recovered hibernating myocardium. (Cardiol J 2008; 15: 261–267)
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Introduction
Ischemic heart disease and its complications
are the main cause of heart failure (HF) in western
societies. Ventricular arrhythmias are frequent in
these patients. It is also well known that patients
in better functional classes (classes I and II of the
New York Heart Association, NYHA) tend to die sud-
denly, while people in worse NYHA classes (III–IV)
tend to do so because of pump failure [1–3]. Such
differentiated behaviour implies different risk profi-
les according to the stage of HF that the patient is in.
This concept is similar to the one of time-depen-
dence risk described for ventricular arrhythmias in
patients with ischemic heart disease [4]. Another
observation is that lower functional classes tend to
be associated with better left ventricle ejection frac-
tions (LVEF) but this is not a golden rule. These
differentiated behaviours could be partially expla-
ined by the arousal of several neurohumoral com-
pensatory mechanisms (renin-angiotensin-aldoste-
rone system activation, liberation of cytokines and
inflammatory mediators, among others) that are
finally associated with an increase in plasmatic ca-
thecholamines. It is also known that modifications
in the neurohumoral profile induce changes in the
activity of the autonomic nervous system that can
in turn be evaluated by several non-invasive tools.
The bottom line is that more sympathetic activity
is related to higher lethal ventricular arrhythmia
risk, especially in the context of a damaged myocar-
dium that cannot sustain cardiac output in the pre-
sence of high ventricular rates with short diastolic
intervals [1, 5–8].
Several tools have been described to evaluate
the sympathetic-parasympathetic equilibrium in
patients with HF. Signal-averaged ECG, QT disper-
sion, heart rate variability and T wave alternans
among others have been used, but possibly the most
simple to clinically acquire and interpret is heart
rate variability in the time-domain. This parameter
is reduced among patients with increased sympa-
thetic activity, such as those with HF. All those
measurements, along with LVEF, NYHA functio-
nal class and the arrhythmic profile, allow the esta-
blishment of a risk profile in HF patients and the
definition of low or high risk for sudden cardiac
death [4]. Nevertheless, it is not well defined how
medical treatment modifies the risk profile. It is
assumed that pharmacological measures directed
towards a better neurohumoral condition in these
patients should have a positive influence on their
arrhythmic profile [9–14]. Traditionally, the num-
ber and characteristics of the ventricular arrhyth-
mias has been associated with increased arrhyth-
mic risk; nevertheless, risk stratification continu-
es to be controversial [15–18].
In a preliminary work, we reported that patients
receiving pharmacological treatment for HF showed
an increase in the number of ventricular arrhythmias
in a medium-term follow-up (one year) [19]. A po-
ssible explanation for such apparently paradoxical
behaviour could be the recovery of hibernating
or ischemic myocardium.
Methods
We carried out a prospective observational stu-
dy in 90 consecutive patients with HF that had ba-
seline Holter monitoring and at least another con-
trol study in a two-year lapse. All of them were sta-
ble patients (NYHA I–III) that assisted to the
outpatient Heart Failure Clinic (HFC) of the insti-
tute. The group included 56 men (62.2%) and
34 women. The mean age of the study population was
60.8 ± 14.6 (range 20 to 83) years at baseline and
62.7 ± 14.8 (range 22–83) years at follow-up. All of
them were started on a standardized pharmacolo-
gical treatment (diuretics, angiotensin converting
enzyme inhibitors — ACEI, angiotensin receptor
blockers — ARB, aldosterone blockers, digitalis and
beta-adrenoceptor blockers) aimed at heart failure.
Chronic stable ischemic heart disease was found in
53 (58.9%) of them. None had unstable angina or acu-
te coronary events in the three months prior to inclu-
sion. Fifty-one ischemic patients (56.7%) had had
a revascularization procedure (angioplasty or throm-
bolysis) related to an acute myocardial infarction at
least three months prior to inclusion in the HFC.
Routine Holter controls are made at different
intervals to evaluate clinical changes in the arrhy-
thmic profile. Such intervals are dictated by the time
it takes for the patient to reach an individualized
maximal dosage of all the medications used (opti-
mal pharmacological treatment), but it also depends
on stabilization of their clinical condition and on
their adherence to follow-up visits. Every patient
that showed a high ventricular arrhythmia risk at
baseline (complex arrhythmias), as well as those
who required specific antiarrhythmic treatment,
were not included in the study.
From the Holter monitoring we recorded ma-
ximal (HRmax), minimal (HRmin) and average he-
art rate (HRa), as well as a heart rate dispersion
value (HRdisp) obtained from the difference betwe-
en maximal and minimal heart rates. We also regi-
stered heart rate variability parameters in time
domains, such as the standard deviation of each
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normal to normal beat (SDNN), average of the stan-
dard deviation of each normal to normal beat in five-
minute intervals (ASDNN5) and the standard de-
viation of the average of each normal to normal beat
interval in five minutes (SDANN5). We also regi-
stered the number of supraventricular premature
beats (SVPC) and ventricular premature comple-
xes in the 24-hour Holter recording, considering
the total number of SVPCs and premature ventri-
cular contractions (PVCs) in 24 hours and the ho-
urly average.
We compared the baseline measurements with
those of the follow-up, and the intervals were divided
in controls: less than 6 months from baseline, 6 mon-
ths to one year, one year to 18 months and more than
18 months. Every patient was his/her own control.
On the other hand, myocardial perfusion scans
with Tc-99m (sestaMIBI) with rest/stress (dypiri-
damole) protocol using conventional technique
were performed at baseline and during follow-up in
35 subjects.
The study was approved by the local bioethi-
cal committe and all patients gave their informed
consent.
Statistical analysis
Continuous variables are expressed as mean ±
± standard deviation and the categorical variables
as percentages. To compare between measure-
ments in the same subject we used Student’s T test
for related samples. To compare means we used in-
dependent samples for Student’s T test and varian-
ce analysis (ANOVA). A p value < 0.05 was consi-
dered significant. We used the SPSS Inc. 10.0 sta-
tistical package to calculate statistics.
Results
Among the included patients, 57 (65.5%) were
in NYHA functional class I, 17 (19.5%) in functio-
nal class II and 11 (12.6%) in class III. The mean
LVEF was 39.1 ± 15.2%. Forty-seven (54%) pa-
tients had systolic dysfunction, 17 (19.5%) had dia-
stolic dysfunction and 18 (20.7%) had mixed dys-
function. Only three cases (3.4%) had right heart
failure. The remaining patient characteristics are
shown in Table 1, along with the drugs they rece-
ived during HFC follow-up.
The mean interval between baseline and first
follow-up Holter was 20.7 ± 17.3 months, and the
interval between the baseline and a second follow-
up study was 44.3 ± 22.8 months. Table 2 summa-
rizes the main values for heart rate and heart rate
variability, specifically SDNN since ASDNN5 and
SDANN5 did not show significant differences and
were eliminated from further analysis.
The mean PVCs number in the baseline Hol-
ter was 1197.8 ± 3026.8 (range 0 to 21078) and
1241.09 ± 3640.15 (range 0 to 27971, p = NS) in
the first follow-up Holter. The mean minute count
was 0.8 ± 2.1 PVCs at baseline and 0.86 ± 2.5 at
follow-up (p = NS). Supraventricular premature
beats were 278.7 ± 680.9 daily at baseline and
Table 1. Patient’s characteristics.
Baseline characteristics
Age (mean ± SD) 60.8 ± 14.6
Male patients 56 (62.2%)
Previous MI 51 (56.7%)
Diabetes 42 (46.7%)
Hypertension 59 (65.5%)
Dyslipidemia 70 (77.8%)
Left ventricular ejection fraction 39.1 ± 15.2%
Medications used during
HFC follow-up
Beta-blockers 83 (92.2%)
ACE inhibitors/ARB’s 89 (98.9%)
Thyazide diuretics 58 (64.4%)
Loop diuretics 15 (16.7%)
Digitalis 65 (72.2%)
Oral nitrates 38 (42.2%)
Amiodarone 6 (6.7%)
Anticoagulation 5 (5.6%)
MI — myocardial infarction; HFC — Heart Failure Clinic; ACE — angio-
tensin converting enzyme; ARB — angiotensin receptor blockers
Table 2. Heart rate and time-domain variability
values.
Parameter Mean ± SD p Range
(min.–max.)
HRmax 1 109.1 ± 20.8 74–176
HRmax 2 104.9 ± 20.9 0.2 55–167
HRmin 1 49.9 ± 10.5 31–77
HRmin 2 49.8 ± 12.5 0.9 30–108
HRmean 1 70.3 ± 10.2 49–97
HRmean 2 68.6 ± 12.04 0.1 37–98
HRdisp 1 59.2 ± 23.02 22–134
HRdisp 2 57.2 ± 24.7 0.2 20–161
SDNN 1 160.2 ± 83.2 37.1–369.3
SDNN 2 154.2 ± 118.5 0.5 37.1–796.8
LP 1 1.4 ± 0.3 1.1–2
LP 2 1.7 ± 0.5 0.5 0.9–3.1
HR — heart rate; SDNN — standard deviation of each normal to nor-
mal beat; LP — longest pause
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310.6 ± 686 at follow-up (p = NS). Table 3 shows
the behaviour of premature beats separated by
month intervals between baseline and first follow-
-up studies, as well as heart rate parameters and he-
art rate variability. Six patients (6.7%) showed ven-
tricular triplets in the first follow-up control (3.2 ±
± 1.2 episodes) that prompted antiarrhythmic tre-
atment. A third control study for them showed PVCs
but no complex arrhythmias.
Seventeen patients had a second control. In
4 of them it was performed before 18 months and
in the remaining 13 it was done after that period.
Among these patients, the number of PVCs in
24 hours went from 4238 ± 4232.9 at baseline to
689 ± 1182.6 in the first control at 8 months (p =
= 0.1) and to 1444.5 ± 2330.4 (p = 0.2) in a second
control at 14 months. Heart rate variability did not
show any significant changes. In the remaining
13 patients, the second control was performed
a mean of 51.4 ± 18.2 months after the baseline stu-
dy. The number of PVCs went from 2298.5 ± 5801.1
at baseline to 2799.3 ± 7672.1 in the first (p = 0.5)
and diminished to 2590.5 ± 7273.8 in the second
control (p=0.4). Heart rate variability (SDNN) went
from 194.7 ± 86.5 ms to 137.4 ± 73.8 ms (p = 0.04)
in the first control and to 116.1 ± 38.03 ms in the
second control (p = 0.3 between controls and p = 0.01
between baseline and second control). Nonetheless,
all of these values are within normal range.
In thirty-five patients we performed a control
myocardial perfusion scintigraphy 2.4 ± 1.5 years
after the baseline one. The mean number of affec-
ted territories went from 8.8 ± 5.09 to 8.6 ± 5.3
(p = NS). When the type of lesion was differentia-
ted, it was found that the territories showing a re-
verse redistribution pattern went from 0.46 ± 2.2
to 1.49 ± 2.91 (p = 0.03), while the number of ische-
mic territories went from 4.97 ± 4.67 to 3.6 ± 4.1
(p = 0.06). The number of necrotic territories did
not show significant changes: 3.5 ± 3.79 vs. 3.5 ±4.2
(p = NS). Table 4 shows a comparison of the perfu-
sory changes and the number of PVCs, taking into
account the different periods between studies.
Discussion
These findings show a tendency towards an
increase in the number of PVCs during the first year
of treatment in the HFC that later on tend to dimi-
nish and stabilize. Possibly this risk profile modifi-
cation is influenced by the therapeutic intervention
and even with the progression of the disease. No-
wadays, HF treatment pretends to modify the neu-
rohumoral profile of these patients through chan-Ta
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ges in intracavitary pressures (pre-load), a reduc-
tion in the after-load (vasodilators, ACEI, ARB),
a reduction in the effects of aldosterone (spirono-
lactone), a reduction in fibrosis and atrial and ven-
tricular remodelling (ACEI, ARB, spironolactone)
and an optimization of myocardial perfusion in ische-
mic patients, reducing myocardial oxygen consump-
tion (beta-adrenoceptor blockers, nitrates) [1].
Without regard to the etiology, virtually every subject
with HF shows perfusion abnormalities suggestive
of ischemia or other forms of endothelial dysfunc-
tion less well defined, such as reverse redistribu-
tion, that can in turn be early expressions of that
problem, possibly related to increases in the wall-
stress or higher myocardial oxygen consumption.
Pharmacological treatment of heart failure en-
hances myocardial perfusion, especially among tho-
se with an ischemic origin, through a reduction in
the number of areas with hibernating or contused
myocardium and the periods of contusion related to
reperfusion damage. The present results confirm
the previous findings of our group in which rever-
se redistribution was associated with a reduction in
NYHA functional class and LVEF, giving clinical
relevance to the perfusion abnormalities [20]. On
the other hand, it suggests that the reduction in the
ischemic territories takes place in accordance with
an increase in those territories that show reverse
redistribution, without changes in necrotic areas.
Such changes could be involved in the genesis of
electric instability and could also explain the tem-
porary pattern of arrhythmia presence that could be
related to a beneficial effect on functional myocyte
recovery derived from early treatment.
Our findings are in apparent contradiction with
those of the SAVE trial [21]; for example, were they
found a consistent increase related to time progres-
sion of HF and apparently induced by left ventricu-
lar remodelling and without any favourable change
induced by ACE inhibition or beta-blocking agents.
The sample size did not allow the detection of any
beneficial effect. Our sample is smaller but the pa-
tients received a combination of medications in an
intensive treatment. In the long-term follow-up,
arrhythmias stabilized but did not show a continu-
ously decreasing pattern that could be in relative
accordance with the above-mentioned results.
The initial reduction could be explained by tre-
atment-induced acute changes in the neurohumo-
ral variables, as well as by some antiarrhythmic ef-
fect from beta blockers and possibly ARB (since
irbesartan is associated with a reduction in the
Table 4. Number of scintigraphy-detected affected territories and premature ventricular contractions
(PVCs) according to time intervals between baseline Holter and controls.
Baseline Holter Baseline Holter Baseline Holter Baseline Holter
vs. control less vs. control  vs. 1 year vs. control more
 than 6 months 6 months 1 year  to 18 months  than 18 months
Sum of territories with 0 ± 0 0.18 ± 0.6 0.5 ± 1.22 1.1 ± 1.8
reverse redistribution,
baseline
Sum of territories with 1.25 ± 2.38 2.09 ± 4.01 1.17 ± 1.8 1.2 ± 2.7
reverse redistribution, (p = 0.1)  (p = 0.1) (p = 0.3) (p = 0.9)
control
Sum of ischemic 3.25 ± 2.55 5.64 ± 5.94 7.17 ± 4.75 4.3 ± 4.3
territories, baseline
Sum of ischemic 1.25 ± 1.8 3.18 ± 3.09 3.8 ± 6.27 5.8 ± 6.2
territories, control  (p = 0.04)  (p = 0.1) (p = 0.05) (p = 0.2)
Sum of necrotic 5.1 ± 3.6 2.55 ± 3.45 4.5 ± 5.1 2.8 ± 3.5
territories, baseline
Sum of necrotic 4.75 ± 3.41 3.91 ± 4.99 1.17 ± 1.6 3.6 ± 5.1
territories, control  (p = 0.7)  (p = 0.4)  (p = 0.08)  (p = 0.5)
Sum of affected 8.4 ± 3.34 8.36 ± 6.12 12.2 ± 4.7 8.2 ± 4.8
territories, baseline
Sum of affected 7.25 ± 3.73 9.18 ± 4.6 6.2 ± 6.1 10.6 ± 6.35
territories, control  (p = 0.7) (p = 0.06)  (p = 0.02)  (p = 0.2)
Number of PVCs, 1053 ± 2020.2 1915.4 ± 4686.9 781.6 ± 1082.4 950.1 ± 2416.6
baseline
Number of PVCs, 746.7 ± 1924.3 2956.3 ± 4248.1 146.9 ± 184.1 666.9 ± 1719.2
control  (p = 0.6) (p = 0.09)  (p = 0.05) (p = 0.2)
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incidence of atrial fibrillation). Later on, hibernating
myocardium recovery with somehow unstable
membranes or local electrolytic changes and incre-
ased differences in refractory periods and local au-
tomatism could explain the later presence of more
arrhythmias [22, 23]. In another previous work, it
was also found that there was a relation between
the increase of ventricular arrhythmias and a reduc-
tion in the number of ischemia-affected territories [19].
The present work suggests that reverse redistribu-
tion that could be related with endothelial dysfunc-
tion happens in a somehow “critical” period from an
“arrhythmic standpoint” and so could support the
thesis that arrhythmia risk increases with hiberna-
ting myocardium recovery to stabilize after that. The
mild increase in the number of necrotic territories,
although non-significant, could explain the reduced
abnormal automatism, but also an increase in re-en-
try arrhythmias since those areas establish fixed
slow-conduction / normal conduction zones [21].
Such findings are relevant in countries such as
ours, since the use of implantable cardioverter-
-defibrillators (ICD) is limited because of socio-eco-
nomic factors. The ICD has a clear positive influ-
ence on survival, but it apparently does not avoid
progression towards pump-failure [24–29]. It has
also been described somewhere else that ICD are
especially useful during the first year after an ische-
mic event; the permanence of the device could be
re-evaluated once this “critical period” has finished.
On the other hand, pharmacological measures to
control arrhythmias should be reinforced during
that period, although the CAST results must be kept
in mind when choosing antiarrhythmics [30, 31].
It is also important to emphasize that high-risk sub-
jects (non-sustained ventricular tachycardias with
low LVEF, people who have recovered from sud-
den death or subjects with other MADIT II crite-
ria) must receive an ICD since survival benefits are
widely demonstrated, but findings such as these
could help re-define high-risk criteria on a dynamic
temporary basis.
One limitation of the study is the HFC popula-
tion itself, which consists mainly of people from low
socio-economic strata who do not live in this city.
Because of this, control appointments are irregu-
lar. The sample size is another limitation, but com-
plete cases show useful information. The different
timing between Holter and scintigraphy itself can
be a confusing factor, even if the apparent relation
between the arrhythmic profile and scintigraphic
changes seems consistent.
Conclusions
In conclusion, the arrhythmic profile of pa-
tients with HF seems to have a dynamic, tempo-
rary profile that is associated with favourable chan-
ges in the myocardial perfusion pattern, even in
the presence of an apparent stability of the main
heart condition.
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